A CRO's Project Manager is Often the Key to Successful Business Procurement
Applied Clinical Trials
ISR's research consistently finds that a CRO's Project Manager often makes the difference between winning and losing a project for the service provider. Not only the number of years experience, or the number of similar projects managed, but also the communication skills and style demonstrated throughout the bidding process.
ISR's research consistently finds that a CRO's Project Manager often makes the difference between winning and losing a project for the service provider. Not only the number of years experience, or the number of similar projects managed, but also the communication skills and style demonstrated throughout the bidding process.
Sponsors Rate Project Manager Quality
In a recent study of the central labs market (See: The State of the Central Labs Market; www.isrreports.com) the impact that a Project Manager has on sponsors' experiences throughout the delivery of a project was examined. This chart illustrates the high degree to which central lab project management is correlated with overall delivery quality (although the brands are obscured in this article). Service providers with highly rated PMs also tend to receive higher overall quality ratings.
If you are a service provider and want to differentiate your offering based on quality, then hire and train the best Project Managers you can find. If you are a sponsor and you want the highest quality central lab experience, then make sure you get the service provider's best Project Managers.
—Industry Standard Research, www.isrreports.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
